Safety and efficacy of a quinolone-based regimen for treatment of tuberculosis in renal transplant recipients.
Transplant Proc
; 44(3): 730-3, 2012 Apr.
Article
em En
| MEDLINE
| ID: mdl-22483479
ABSTRACT
BACKGROUND:
Rifampin (RFP) is a first-line antituberculosis drug, but it increases the risk of acute rejection (AR) in transplant recipients. This study evaluated whether quinolone (QNL) can replace RFP in renal transplant recipients with tuberculosis.METHODS:
One hundred nine patients with active tuberculosis were included. Patients consisted of RFP (n = 91) and QNL (n = 18) groups based on the initial treatment regimen. Patients with RFP-associated adverse effects were subdivided into RFP-maintenance (RFP-M; n = 18) and QNL-conversion (QNL-C; n = 8) groups. Clinical outcomes were compared between groups.RESULTS:
The incidence of AR was higher in the RFP group than in the QNL group (24.2% vs 5.6%). The QNL group showed significantly higher 10-year graft survival rates than the RFP group (88.1% vs 66.5%; P = .022). The QNL-C group showed significantly higher 10-year graft survival rates than the RFP-M group (87.5% vs 27.8%; P = .011). The rate of complete functional recovery after AR was higher in the QNL-C group than in the RFP-M group (50% vs 22.2%).CONCLUSIONS:
A QNL-based regimen may be safe and effective for treatment of tuberculosis and may lower the risk of graft failure in renal transplant recipients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tuberculose
/
Transplante de Rim
/
Quinolonas
/
Antituberculosos
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article